Hardenbergh Dylan, Naik Rakhi, Manno Rebecca, Azar Antoine, Monroy Trujillo Jose Manuel, Adler Brittany, Haque Uzma, Timlin Homa
From the Johns Hopkins University School of Medicine.
Divisions of Hematology.
J Clin Rheumatol. 2022 Jan 1;28(1):e257-e262. doi: 10.1097/RHU.0000000000001729.
Systemic lupus erythematosus (SLE) patients have a well-established increased risk for cancer. Research from the past 2 decades has identified the specific malignancies that afflict SLE patients at disproportionate rates. Systemic lupus erythematosus patients are at heightened risk for several hematologic malignancies as well as for certain solid tumors, including lung, thyroid, and hepatobiliary cancers. They are at decreased risk for several cancers as well, including prostate and melanoma. Improved understanding of the unique cancer risk profile of SLE patients has led some professional societies to recommend specialized cancer screening and prevention measures for these patients and has enabled clinicians to better serve the SLE patient population.
系统性红斑狼疮(SLE)患者患癌症的风险显著增加,这一点已得到充分证实。过去20年的研究已经明确了那些在SLE患者中发病率过高的特定恶性肿瘤。系统性红斑狼疮患者患几种血液系统恶性肿瘤以及某些实体瘤(包括肺癌、甲状腺癌和肝胆癌)的风险增加。他们患某些癌症的风险也较低,包括前列腺癌和黑色素瘤。对SLE患者独特的癌症风险特征的进一步了解,促使一些专业协会为这些患者推荐专门的癌症筛查和预防措施,并使临床医生能够更好地为SLE患者群体提供服务。